Developer docs
API playgroundTry for free, no card

Search company profiles

MemoText

Full company profile

uuid000yneo

Namestring
MemoText
Legal namestring
MEMOTEXT Corporation
Websiteurl
memotext.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

MEMOTEXT Corporation is a Toronto-based digital health company founded by Amos Adler that operates a data-driven, evidence-based platform for personalized patient engagement and digital therapeutics. The platform enables co-creation of omnichannel digital health programs across SMS, mobile applications, WhatsApp, and voice assistants (including Amazon Alexa via the Ring of Support sub-brand), with predictive analytics driving personalization from multi-source inputs including prescription drug claims, wearable device data (Fitbit), ambient mobile/sleep data, EMR data, and behavioral responses. The company's product portfolio is structured as a core platform plus a Creator co-build tool, a Digital Health Marketplace of validated interventions, and a set of sub-branded programs — most notably the A4i (App4Independence) digital therapeutic for schizophrenia and psychosis, operated through a 2016 joint venture (A4i Inc.) with the Centre for Addiction and Mental Health. Other modules include BeWell/Be SaskWell (mental health check-ins, co-created with CAMH and University of Saskatchewan), Resources Around Me (youth mental health resource search engine with Kids Help Phone), Ring of Support (mild cognitive impairment/dementia support with SE Health), SOFIA (SMS intervention for pediatric ADHD adherence), and the recently launched MTxPERT and mtxt.ai generative-AI products.

The company sells primarily to enterprise clients — health systems, mental health centers, pharmaceutical companies, payers, and academic medical centers — under a platform-as-a-service ("MEMOTEXT as a Service" / MaaS) co-creation model, complemented by co-commercialization of pre-validated marketplace solutions. Go-to-market is direct enterprise field sales supported by long-cycle co-development partnerships with named logos including McKesson Canada, SE Health, Novartis Canada, Genentech/Roche, Humana, Green Shield Canada, Boots/Walgreens UK, Johns Hopkins, Vanderbilt, Mass General/Partners Healthcare, SickKids, BC Children's Hospital, and Riverside University Health System. The company holds a patent-pending auditory hallucination detection algorithm and maintains HIPAA, PIPEDA, PHIPA, and GDPR compliance. MEMOTEXT remains a privately-held, founder-led company with 11–50 employees, dual headquarters in Toronto (Canada) and Bethesda, MD (US), and no disclosed institutional funding rounds.

Short descriptiontext

MEMOTEXT Corporation is a Toronto-based digital health platform company that co-creates and commercializes personalized, omnichannel patient-engagement programs and digital therapeutics — most notably the A4i schizophrenia DTx via a CAMH joint venture — for enterprise health systems, pharma, payers, and academic medical centers across North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital patient engagement, digital therapeutics platform, medication adherence software, behavioral health technology, healthcare co-creation platform
Industry4 codes
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACADAH
Patient Communications (Reminders/Confirmations/Recalls)
NAICS code2 codes
  • Custom Computer Programming Services541511
  • Management Consulting Services54161
SIC code2 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Computer Programming Services7371
Product category
Digital Patient Engagement and Digital Therapeutics Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform as a Service (MaaS)
TypeSubscription Recurring
Description

MEMOTEXT as a service enables academics/clinicians and commercial partners to co-create interactive, adaptive, evidence-based engagement communications and digital therapeutics (DTx). They co-commercialize interventions with provider, insurer and pharmaceutical clients on their developing library of digital interventions (digital formulary).

memotext.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1App4Independence (A4i)
Description

Validated digital therapeutic mobile app and clinical portal for severe mental illness (schizophrenia, psychosis), featuring auditory hallucination detection, readmission risk prediction, and care coordination tools.

memotext.com
+5 more records
Core offering1 text field

MEMOTEXT provides a data-driven, evidence-based personalized digital patient engagement and digital therapeutics (DTx) platform that uses health data (claims, wearables, EMRs, ambient phone data) for risk identification and treatment adherence personalization. The company enables academics, clinicians, and commercial partners to co-create interactive, adaptive, omni-channel engagement communications delivered through SMS, mobile applications, WhatsApp, and voice assistants, and it maintains a marketplace of pre-validated digital interventions for mental health, maternal health, ADHD, hypertension, and dementia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 31.4% medication adherence improvement in randomized control study with Johns Hopkins University
+4 more records
Product overview1 text field

MEMOTEXT is a co-creation digital patient engagement and digital therapeutics platform that operates on a platform-plus-modules architecture. The core MEMOTEXT Platform serves as the foundational technology enabling omnichannel engagement (SMS, mobile app, WhatsApp, voice assistants) powered by predictive analytics and personalization. The platform is extended through the Creator tool (for building custom solutions) and a Marketplace of validated, co-commercialized programs. The product portfolio includes named sub-brands and modules: A4i (a joint-venture digital therapeutic with CAMH for schizophrenia), MTxPERT (AI chatbot assistant), mtxt.ai (AI acceleration layer), Ring of Support (Alexa-powered dementia support platform), BeWell (CAMH/University of Saskatchewan mental health navigator), Resources Around Me (Kids Help Phone youth mental health resource platform), and a COVID-19 assessment solution.

Product and service2 records
1MEMOTEXT Platform
CategoryCore platform
2Creator / Creator Components
CategoryPlatform
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Partnership combining STI's innovative healthcare solutions with MEMOTEXT's personalized engagement technology to enhance patient experience in patient support programs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-11
Description

Collaboration with Dr. Frank Schwebel at CASAA on digital health tools to support opioid recovery and pain management.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-12
Description

OBIO-supported partnership to expand A4i Canadian presence across health systems.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-04
Description

Six-month pilot to determine feasibility of deploying A4i in California community mental health clinics at scale. Part of Help@Hand statewide collaborative program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-04
Description

California City and County Collaborative to determine if and how technology fits within behavioral health system of care. Partnership to scale A4i across California.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-05-11
Description

Joint venture A4i Inc. created to develop and commercialize award-winning mobile health intervention for schizophrenia. CAMH is Canada's largest mental health teaching hospital. Partnership involves co-development of digital therapeutic platform with clinical and scientific leadership.

7A4i Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture company between CAMH and MEMOTEXT to commercialize App4Independence digital therapeutic for schizophrenia and psychosis spectrum illnesses. Led by cross-functional team of digital health, clinical and commercialization experts.

memotext.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-creation of BeWell mental health text-messaging program promoting curated mental health resources and wellness supports. Validated in CIHR-funded study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration supporting development and launch of Resources Around Me platform - Canada's largest search engine for youth mental health resources.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

One-year evaluation project with The Royal exploring feasibility of integrating A4i app and clinical portal into clinical practice at Ozerdinc Grimes Family Regional Psychosis Clinic. Funded by OBIO's EAHN.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Home health partnership including care coordination solutions and Ring of Support voice assistant platform for seniors with mild cognitive impairment or early-stage dementia.

12Vanderbilt University Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

10+ year academic partnership with Dr. Lindsay Mayberry for patient engagement research and validation of digital health solutions.

memotext.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Stick2it program collaboration for medication adherence to cholesterol and hypertension medications with measurable outcomes.

Strategic tierCoreTypeGTM or Marketing Partner
Description

OBIO Early Adopter Health Network (EAHN) partnership to facilitate technology adoption in Canadian mental healthcare market.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large mental health platform combining consumer content, employer/payer distribution, and digital therapeutic programs (e.g., for depression). Comparable to MEMOTEXT's mental-health DTx portfolio and enterprise health-plan engagement model.

TypeBroad incumbent
Description

Digital therapeutics and connected-device platform for respiratory conditions (now part of ResMed), focused on medication adherence and patient engagement. Comparable in using sensor data and predictive analytics to drive adherence outcomes.

TypeDirect peer
Description

Chronic care digital therapeutics platform (BlueStar for diabetes) combining patient engagement, predictive analytics, and clinical decision support. Comparable in using multi-source data (claims, devices) for personalized engagement across chronic conditions.

TypeDirect peer
Description

Public DTx company with FDA-cleared prescription digital therapeutics (EndeavorRx for pediatric ADHD) and a broader cognitive DTx pipeline. Directly comparable to MEMOTEXT in building evidence-based, condition-specific DTx for ADHD and mental health via enterprise and pharma channels.

TypeDirect peer
Description

Prescription digital therapeutics company developing software-based treatments across migraine, schizophrenia, and other indications, with pharma co-commercialization. Closely comparable to MEMOTEXT's evidence-based DTx development model and enterprise pharma positioning.

TypeBroad incumbent
Description

Larger, venture-backed DTx incumbent focused on diabetes prevention, hypertension, and behavioral health, with payer and employer channels. Comparable to MEMOTEXT's chronic-condition DTx formulary and payer/insurer go-to-market, though at substantially greater scale.

TypeDirect peer
Description

Digital therapeutics company (now part of AptarGroup) developing SaMD for chronic conditions including oncology and diabetes, with pharma partnerships. Directly comparable to MEMOTEXT's co-created SaMD model with pharma and provider customers.

TypeDirect peer
Description

Medication adherence and patient engagement platform with predictive analytics and pharma partnerships. Closely comparable to MEMOTEXT's foundational medication-adherence business and omni-channel engagement approach.

TypeEmerging player
Description

Digital mental health platform offering prescription and non-prescription digital therapeutics alongside employer/payer distribution. Comparable to MEMOTEXT's mental-health engagement solutions and pharma/payer enterprise motion.

TypeDirect peer
Description

Digital therapeutics company with Sleepio (insomnia) and Daylight (anxiety) products, distributed via payers, providers, and employers. Comparable to MEMOTEXT's mental-health DTx positioning and enterprise health plan channel strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers19 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MemoText

Digital Patient Engagement and Digital Therapeutics Softwarememotext.com

MEMOTEXT Corporation is a Toronto-based digital health platform company that co-creates and commercializes personalized, omnichannel patient-engagement programs and digital therapeutics — most notably the A4i schizophrenia DTx via a CAMH joint venture — for enterprise health systems, pharma, payers, and academic medical centers across North America.

What MemoText does

MEMOTEXT Corporation is a Toronto-based digital health company founded by Amos Adler that operates a data-driven, evidence-based platform for personalized patient engagement and digital therapeutics. The platform enables co-creation of omnichannel digital health programs across SMS, mobile applications, WhatsApp, and voice assistants (including Amazon Alexa via the Ring of Support sub-brand), with predictive analytics driving personalization from multi-source inputs including prescription drug claims, wearable device data (Fitbit), ambient mobile/sleep data, EMR data, and behavioral responses. The company's product portfolio is structured as a core platform plus a Creator co-build tool, a Digital Health Marketplace of validated interventions, and a set of sub-branded programs — most notably the A4i (App4Independence) digital therapeutic for schizophrenia and psychosis, operated through a 2016 joint venture (A4i Inc.) with the Centre for Addiction and Mental Health. Other modules include BeWell/Be SaskWell (mental health check-ins, co-created with CAMH and University of Saskatchewan), Resources Around Me (youth mental health resource search engine with Kids Help Phone), Ring of Support (mild cognitive impairment/dementia support with SE Health), SOFIA (SMS intervention for pediatric ADHD adherence), and the recently launched MTxPERT and mtxt.ai generative-AI products.

The company sells primarily to enterprise clients — health systems, mental health centers, pharmaceutical companies, payers, and academic medical centers — under a platform-as-a-service ("MEMOTEXT as a Service" / MaaS) co-creation model, complemented by co-commercialization of pre-validated marketplace solutions. Go-to-market is direct enterprise field sales supported by long-cycle co-development partnerships with named logos including McKesson Canada, SE Health, Novartis Canada, Genentech/Roche, Humana, Green Shield Canada, Boots/Walgreens UK, Johns Hopkins, Vanderbilt, Mass General/Partners Healthcare, SickKids, BC Children's Hospital, and Riverside University Health System. The company holds a patent-pending auditory hallucination detection algorithm and maintains HIPAA, PIPEDA, PHIPA, and GDPR compliance. MEMOTEXT remains a privately-held, founder-led company with 11–50 employees, dual headquarters in Toronto (Canada) and Bethesda, MD (US), and no disclosed institutional funding rounds.

MemoText firmographics

Firmographics
Name
MemoText
Legal name
MEMOTEXT Corporation
Website
https://memotext.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
MEMOTEXT Corporation is a Toronto-based digital health platform company that co-creates and commercializes personalized, omnichannel patient-engagement programs and digital therapeutics — most notably the A4i schizophrenia DTx via a CAMH joint venture — for enterprise health systems, pharma, payers, and academic medical centers across North America.
Ownership category
akta.pro rank

MemoText industry classification

Industry
Product category
Digital Patient Engagement and Digital Therapeutics Software
NAICS
Custom Computer Programming Services (541511), Management Consulting Services (54161)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACADAH
Patient Communications (Reminders/Confirmations/Recalls)

Keywords

  • Digital patient engagement
  • Digital therapeutics platform
  • Medication adherence software
  • Behavioral health technology
  • Healthcare co-creation platform

Where MemoText is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

MemoText business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform as a Service (MaaS): MEMOTEXT as a service enables academics/clinicians and commercial partners to co-create interactive, adaptive, evidence-based engagement communications and digital therapeutics (DTx). They co-commercialize interventions with provider, insurer and pharmaceutical clients on their developing library of digital interventions (digital formulary).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

MemoText product offering

Product offering

Core offering

MEMOTEXT provides a data-driven, evidence-based personalized digital patient engagement and digital therapeutics (DTx) platform that uses health data (claims, wearables, EMRs, ambient phone data) for risk identification and treatment adherence personalization. The company enables academics, clinicians, and commercial partners to co-create interactive, adaptive, omni-channel engagement communications delivered through SMS, mobile applications, WhatsApp, and voice assistants, and it maintains a marketplace of pre-validated digital interventions for mental health, maternal health, ADHD, hypertension, and dementia.

Product overview

MEMOTEXT is a co-creation digital patient engagement and digital therapeutics platform that operates on a platform-plus-modules architecture. The core MEMOTEXT Platform serves as the foundational technology enabling omnichannel engagement (SMS, mobile app, WhatsApp, voice assistants) powered by predictive analytics and personalization. The platform is extended through the Creator tool (for building custom solutions) and a Marketplace of validated, co-commercialized programs. The product portfolio includes named sub-brands and modules: A4i (a joint-venture digital therapeutic with CAMH for schizophrenia), MTxPERT (AI chatbot assistant), mtxt.ai (AI acceleration layer), Ring of Support (Alexa-powered dementia support platform), BeWell (CAMH/University of Saskatchewan mental health navigator), Resources Around Me (Kids Help Phone youth mental health resource platform), and a COVID-19 assessment solution.

Differentiator

Problem solved

Functional benefit

Brands

  • App4Independence (A4i): Validated digital therapeutic mobile app and clinical portal for severe mental illness (schizophrenia, psychosis), featuring auditory hallucination detection, readmission risk prediction, and care coordination tools.
  • BeWell
  • SOFIA
  • Ring of Support
  • Resources Around Me
  • MTxPERT

Products and services

  • MEMOTEXT Platform
  • Creator / Creator Components

Quantifiable outcome

  • 31.4% medication adherence improvement in randomized control study with Johns Hopkins University
  • +4 more outcomes

Companies that use MemoText

Customer profile

Named customers19 records

Segments5 records

Ideal customer profiles4 records

MemoText technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability10 records

Feature6 records

MemoText partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • STI Technologies (IQVIA Company)coreStrategic or Co-development Partner · 8 October 2025Partnership combining STI's innovative healthcare solutions with MEMOTEXT's personalized engagement technology to enhance patient experience in patient support programs.
  • University of New MexicominorStrategic or Co-development Partner · 11 July 2025Collaboration with Dr. Frank Schwebel at CASAA on digital health tools to support opioid recovery and pain management.
  • Waypoint Centre for Mental Health CareminorStrategic or Co-development Partner · 12 June 2025OBIO-supported partnership to expand A4i Canadian presence across health systems.
  • Riverside University Health System - Behavioral HealthcoreStrategic or Co-development Partner · 4 November 2021Six-month pilot to determine feasibility of deploying A4i in California community mental health clinics at scale. Part of Help@Hand statewide collaborative program.
  • CalMHSA Help@HandcoreStrategic or Co-development Partner · 4 November 2021California City and County Collaborative to determine if and how technology fits within behavioral health system of care. Partnership to scale A4i across California.
  • Centre for Addiction and Mental Health (CAMH)coreStrategic or Co-development Partner · 11 May 2016Joint venture A4i Inc. created to develop and commercialize award-winning mobile health intervention for schizophrenia. CAMH is Canada's largest mental health teaching hospital. Partnership involves co-development of digital therapeutic platform with clinical and scientific leadership.
  • A4i Inc.coreStrategic or Co-development PartnerJoint venture company between CAMH and MEMOTEXT to commercialize App4Independence digital therapeutic for schizophrenia and psychosis spectrum illnesses. Led by cross-functional team of digital health, clinical and commercialization experts.
  • University of SaskatchewancoreStrategic or Co-development PartnerCo-creation of BeWell mental health text-messaging program promoting curated mental health resources and wellness supports. Validated in CIHR-funded study.
  • Kids Help PhonecoreStrategic or Co-development PartnerCollaboration supporting development and launch of Resources Around Me platform - Canada's largest search engine for youth mental health resources.
  • The Royal Ottawa Mental Health CentrecoreStrategic or Co-development PartnerOne-year evaluation project with The Royal exploring feasibility of integrating A4i app and clinical portal into clinical practice at Ozerdinc Grimes Family Regional Psychosis Clinic. Funded by OBIO's EAHN.
  • SE HealthcoreStrategic or Co-development PartnerHome health partnership including care coordination solutions and Ring of Support voice assistant platform for seniors with mild cognitive impairment or early-stage dementia.
  • Vanderbilt University Medical CentercoreStrategic or Co-development Partner10+ year academic partnership with Dr. Lindsay Mayberry for patient engagement research and validation of digital health solutions.
  • Green Shield CanadacoreStrategic or Co-development PartnerStick2it program collaboration for medication adherence to cholesterol and hypertension medications with measurable outcomes.
  • Ontario Bioscience Innovation Organization (OBIO)coreGTM or Marketing PartnerOBIO Early Adopter Health Network (EAHN) partnership to facilitate technology adoption in Canadian mental healthcare market.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

MemoText competitors and assessment

Company assessment

Broad incumbents

  • Headspace Health: Large mental health platform combining consumer content, employer/payer distribution, and digital therapeutic programs (e.g., for depression). Comparable to MEMOTEXT's mental-health DTx portfolio and enterprise health-plan engagement model.
  • Propeller Health: Digital therapeutics and connected-device platform for respiratory conditions (now part of ResMed), focused on medication adherence and patient engagement. Comparable in using sensor data and predictive analytics to drive adherence outcomes.
  • Omada Health: Larger, venture-backed DTx incumbent focused on diabetes prevention, hypertension, and behavioral health, with payer and employer channels. Comparable to MEMOTEXT's chronic-condition DTx formulary and payer/insurer go-to-market, though at substantially greater scale.

Direct peers

  • WellDoc: Chronic care digital therapeutics platform (BlueStar for diabetes) combining patient engagement, predictive analytics, and clinical decision support. Comparable in using multi-source data (claims, devices) for personalized engagement across chronic conditions.
  • Akili Interactive: Public DTx company with FDA-cleared prescription digital therapeutics (EndeavorRx for pediatric ADHD) and a broader cognitive DTx pipeline. Directly comparable to MEMOTEXT in building evidence-based, condition-specific DTx for ADHD and mental health via enterprise and pharma channels.
  • Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across migraine, schizophrenia, and other indications, with pharma co-commercialization. Closely comparable to MEMOTEXT's evidence-based DTx development model and enterprise pharma positioning.
  • Voluntis: Digital therapeutics company (now part of AptarGroup) developing SaMD for chronic conditions including oncology and diabetes, with pharma partnerships. Directly comparable to MEMOTEXT's co-created SaMD model with pharma and provider customers.
  • Medisafe: Medication adherence and patient engagement platform with predictive analytics and pharma partnerships. Closely comparable to MEMOTEXT's foundational medication-adherence business and omni-channel engagement approach.
  • Big Health: Digital therapeutics company with Sleepio (insomnia) and Daylight (anxiety) products, distributed via payers, providers, and employers. Comparable to MEMOTEXT's mental-health DTx positioning and enterprise health plan channel strategy.

Emerging players

  • Happify Health: Digital mental health platform offering prescription and non-prescription digital therapeutics alongside employer/payer distribution. Comparable to MEMOTEXT's mental-health engagement solutions and pharma/payer enterprise motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

MemoText social profiles

Digital presence

MemoText compliance and trust

Trust signal

Compliance3 records

MemoText financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MemoText leadership team

Management profile

Number of profiles

Profiles1 record

MemoText subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

MemoText funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MemoText M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MemoText

What does MemoText do?

MEMOTEXT provides a data-driven, evidence-based personalized digital patient engagement and digital therapeutics (DTx) platform that uses health data (claims, wearables, EMRs, ambient phone data) for risk identification and treatment adherence personalization. The company enables academics, clinicians, and commercial partners to co-create interactive, adaptive, omni-channel engagement communications delivered through SMS, mobile applications, WhatsApp, and voice assistants, and it maintains a marketplace of pre-validated digital interventions for mental health, maternal health, ADHD, hypertension, and dementia.

Is MemoText a public or private company?

MemoText is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MemoText founded?

MemoText was founded in 2012. It employs 1 to 10 people.

Where is MemoText based?

MemoText is headquartered in Toronto, Canada, in the North America region.

How does MemoText make money?

One revenue line is on record: platform as a Service (MaaS).

Who are MemoText's main competitors?

Broad incumbents on record are Headspace Health, Propeller Health and Omada Health. Direct peers are WellDoc, Akili Interactive, Click Therapeutics, Voluntis, Medisafe and Big Health. Happify Health is listed as an emerging player.

Does MemoText have an API?

No public API is recorded for MemoText.

What industry is MemoText in?

MemoText's product category is Digital Patient Engagement and Digital Therapeutics Software. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 541511 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales